长链非编码 RNA 面板作为胶质瘤的分子生物标志物。
Long non-coding RNA panel as a molecular biomarker in glioma.
机构信息
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Baqiyatallah University of Medical Sciences, Tehran, Iran.
出版信息
J Egypt Natl Canc Inst. 2021 Oct 25;33(1):31. doi: 10.1186/s43046-021-00090-4.
BACKGROUND
Glioma is one of the most malignant brain tumors, accounting for about half of the gliomas that occur in central nervous system (CNS), originates from the glial tissue of the brain. The aim of the present study was to determine the expression levels of 5 lncRNAs (MDC1-AS1, HOXA11-AS, MALAT1, CASC2, ADAMTS9-AS2) in patients with high-grade glioma in comparison with low grade glioma.
METHODS
This was a retrospective study which determined molecular biomarker on pathologic glioma samples. We examined 100 patients' pathologic block which consisted of 50 pathology samples of high-grade glioma (case group) and control group consisted of 50 pathology samples of low-grade glioma. This research was performed using real time polymerase chain reaction (PCR) technique.
RESULTS
The results showed that the expression of ADAMTS9-AS2 and HOXA11-AS genes significantly increased with increasing tumor grade. Also the expression of CASC2 gene significantly decreased with increasing tumor grade.
CONCLUSIONS
It was concluded that ADAMTS9-AS2 and HOXA11-AS and CASC2 are promising lncRNA markers in prognosis of glioma.
背景
脑胶质瘤是最恶性的脑肿瘤之一，约占中枢神经系统（CNS）中发生的胶质瘤的一半，起源于脑的神经胶质组织。本研究的目的是确定高水平脑胶质瘤患者中 5 个 lncRNAs（MDC1-AS1、HOXA11-AS、MALAT1、CASC2、ADAMTS9-AS2）的表达水平与低级别胶质瘤相比。
方法
这是一项回顾性研究，确定了病理脑肿瘤样本中的分子生物标志物。我们检查了 100 例病理标本，其中包括 50 例高级别脑胶质瘤（病例组）和 50 例低级别脑胶质瘤的对照组。这项研究是使用实时聚合酶链反应（PCR）技术进行的。
结果
结果表明，ADAMTS9-AS2 和 HOXA11-AS 基因的表达随着肿瘤分级的增加而显著增加。CASC2 基因的表达也随着肿瘤分级的增加而显著降低。
结论
综上所述，ADAMTS9-AS2、HOXA11-AS 和 CASC2 是脑胶质瘤预后有希望的 lncRNA 标志物。
Zotero 插件